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Various types of repetitive sequences are dysregulated in cancer. In Ewing sarcoma, the oncogenic fusion protein
EWS-FLI1 induces chromatin features typical of active enhancers at GGAAmicrosatellite repeats, but the function
of these sites has not been directly demonstrated. Here, by combining nascent transcription profiling with epige-
nome editing, we found that a subset of GGAA microsatellite repeats is transcriptionally active in Ewing sarcoma
and that silencing individual repeats abolishes local nascent transcription and leads tomarkedly reduced expression
of putative target genes. Epigenome silencing of these repeat sites does not affect gene expression in unrelated cells,
can prevent the induction of gene expression by EWS-FLI1, and, in the case of a GGAA repeat that controls SOX2
expression from a distance of 470 kb, is sufficient to impair the growth of Ewing sarcoma xenografts. Using an ex-
perimental approach that is broadly applicable to testing different types of repetitive genomic elements, our study
directly demonstrates that specific repeat microsatellites can have critical gene regulation functions in cancer and
thus represent tumor-specific vulnerabilities that may be exploited to develop new therapies.
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Repeat elements constitute a large fraction of the human
genome and for the most part have not been assigned spe-
cific biological functions (Lander et al. 2001; de Koning
et al. 2011). Recent studies have shown widespread epige-
netic and transcriptional dysregulation of repeat elements
in various tumor types (Ting et al. 2011; Riggi et al. 2014;
Rooney et al. 2015; Burns 2017), highlighting the need
to elucidate their role in cellular transformation and tu-
mor progression. However, understanding of their impli-
cation in cancer has been hampered by their repetitive
nature and broad genomic distribution, which constitute
major challenges toward studying specific biological
contributions.
Ewing sarcoma, the second most common pediatric
bone cancer, is characterized by specific chromosomal
translocations that generate fusions between the EWSR1
gene and members of the ETS family of transcription fac-
tors, most commonly FLI1 (Delattre et al. 1992). The
EWS-FLI1 fusion protein has been shown to operate as a
major regulator of chromatin states that can either acti-
vate or repress enhancer activity, depending on the under-
lying DNA sequence of its binding sites (Riggi et al. 2014).
EWS-FLI1 binding is most clearly associated with enhanc-
er activation at a large set of GGAAmicrosatellite repeats
where the fusion protein behaves as a pioneer factor to
induce chromatin opening and the deposition of his-
tone modifications associated with active enhancer ele-
ments (H3K4me1 and H3K27ac) (Gangwal et al. 2008;
Guillon et al. 2009; Riggi et al. 2014; Tomazou et al.
2015; Boulay et al. 2017). Remarkably, the activation of
GGAA microsatellites is highly specific to Ewing sar-
coma, since these sites remain in a closed chromatin con-
formation in all other cell types examined (Riggi et al.
2014). Moreover, we showed recently that the ability to
bind and activate GGAA repeats is a neomorphic property
of EWS-FLI1 that requires the phase transition properties
of the EWS prion-like domain and is not shared by wild-
type FLI1 (Boulay et al. 2017).
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Despite the fact that activeGGAA repeat elements are a
major feature of the epigenomic landscape of Ewing sar-
coma, their functional implication in gene regulation
and tumorigenesis has not been directly demonstrated.
Assessment of the precise functional contributions of
GGAA repeats is thus a key missing link toward our un-
derstanding of gene regulation by EWS-FLI1. To resolve
this issue, we designed an experimental strategy for test-
ing the function of specific repeat enhancer sites by target-
ing immediately adjacent unique genomic sequenceswith
CRISPR/dCas9-KRAB (Gilbert et al. 2013, 2014; Thakore
et al. 2015; Klann et al. 2017). We show that this approach
leads to silencing of repeat elements by local spreading of
repressive H3K9me3marks, which in turn abolishes local
nascent transcription and H3K27ac activation marks and
dramatically decreases the expression of putative target
genes. Moreover, silencing of a single EWS-FLI1-bound
GGAA repeat enhancer 470 kb from the SOX2 locus
was sufficient to impair the growth of Ewing sarcoma xe-
nografts. Taken together, our results directly demonstrate
that specific microsatellite repeats can make critical con-
tributions to oncogenic gene expression programs that are
essential for tumor maintenance.
Results
EWS-FLI1-bound GGAA microsatellites are
transcriptionally active in Ewing sarcoma
EWS-FLI1-bound GGAA repeat microsatellites have been
proposed to operate as distal enhancers in Ewing sarcoma
based on active chromatin features. Given that evidence
of activity at these sites has been observed only in Ewing
sarcoma (Riggi et al. 2014) in association with tumor-
specific phase transitions (Boulay et al. 2017), we sought
to determine whether they exhibit other typical enhancer
features. In particular, local transcription at enhancers has
been shown recently to be a strong indicator of functional
engagement in target gene activation (Li et al. 2016). We
therefore tested for the presence of nascent noncoding
enhancer RNAs (eRNAs) at GGAA repeats in Ewing sar-
coma cells by performing nuclear run-on (NRO) experi-
ments (Roberts et al. 2015) followed by high-throughput
sequencing (NRO-seq).
Our results show that a subset of GGAA repeats, partic-
ularly those with high numbers of repeat units (10 and
above), displayed eRNA expression in Ewing sarcoma
cells (Fig. 1A; Supplemental Fig. S1A). Moreover, EWS-
FLI1 binding strongly predicted transcriptional activity
at GGAA microsatellite repeats (Fig. 1B; Supplemental
Fig. S1B), and these sites had high levels of transcriptional
activity compared with other distal H3K27ac sites (Sup-
plemental Fig. S1C). These signals were also specific,
since analysis of GRO-seq (global run-on [GRO] combined
with high-throughput sequencing) data fromnormal fibro-
blasts did not detect evidence of nascent transcription at
GGAA repeats (Fig. 1C; Supplemental Fig. S1D), whereas
BJ cells exhibited strong GRO-seq signals compared with
Ewing sarcoma cells at other genomic locations (Supple-
mental Fig. S1E; Slobodin et al. 2017). A subset of these
sites was validated by RT–PCR and gel electrophoresis
in two Ewing sarcoma cell lines (Fig. 1D) as well as by
RT-qPCR (real-time quantitative RT–PCR) in spheroid
cultures derived from primary tumors (Supplemental
Fig. S1F). Finally, CRISPR–Cas9-mediated knockout of
EXOSC3, a core member of the exosome complex,
strongly increased eRNA levels detected by RT-qPCR,
demonstrating that the stability of eRNAs associated
with GGAA repeats is regulated by the exosome complex
in Ewing sarcoma, as observed for other eRNAs in differ-
ent models (Fig. 1E; Pefanis et al. 2015).
EWS-FLI1-bound GGAA repeat enhancers thus possess
not only features of active chromatin but also the tran-
scriptional activity that is characteristic of functional
enhancers (see examples in Supplemental Fig. S1G). Im-
portantly, transcriptional activity at GGAA repeat en-
hancers was completely dependent on EWS-FLI1 levels
(Fig. 1F,G; Supplemental Fig. S2A,B, showing intergenic
EWS-FLI1-bound GGAA repeats). Indeed, as observed pre-
viously for the active histone mark H3K27ac (Riggi et al.
2014), nascent transcription was abrogated at these sites
upon EWS-FLI1 knockdown (Supplemental Fig. S2C–E),
concomitant with decreased expression of their neighbor-
ing putative target genes. Nascent transcription can thus
also serve as a powerful complementary measurement of
EWS-FLI1-dependent GGAA repeat activity.
Silencing of specific EWS-FLI1-bound GGAA repeat
enhancers has major effects on local chromatin states
and eRNA transcription
We next sought to epigenetically silence specific GGAA
repeat enhancers using a CRISPR dCas9-KRAB system ca-
pable of inducing focal chromatin-repressive states by a
combination of histone deacetylation and H3K9me3 dep-
osition (Gilbert et al. 2014; Thakore et al. 2015). To design
guide RNAs targeting GGAA repeat-flanking regions, we
focused on EWS-FLI1-bound GGAA repeat enhancers
neighboring a set of the most responsive EWS-FLI1 puta-
tive target genes defined by integrating RNA sequencing
(RNA-seq) gene expression profiles from EWS-FLI1
down-regulation in tumor cell lines (A673 and SKNMC)
and EWS-FLI1 expression in mesenchymal stem cells
(MSCs), a putative cell of origin for this tumor type (Sup-
plemental Fig. S3A,B; Supplemental Table S1; Riggi
et al. 2005, 2008). The majority of these genes was found
within 500 kb of EWS-FLI1-bound GGAA repeat enhanc-
ers in Ewing sarcoma cells (Supplemental Fig. S3C; Sup-
plemental Table S1) and was expressed at very low
levels in MSCs (Supplemental Fig. S3D), where these
geneswere frequently associatedwith theH3K27me3 Pol-
ycomb mark (Supplemental Fig. S3E). Activation of
GGAA microsatellites by introduction of EWS-FLI1 in
MSCs resulted in marked activation of these putative tar-
get promoters (Fig. S3F–H).
To avoid potential nonspecific effects of CRISPR silenc-
ing, genes associated with enhancers found in intragenic
regions or <5 kb from genes expressed in Ewing sarcoma
were removed from consideration. This approach yielded
a total of 27 high-confidence putative target genes
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associated with 30 EWS-FLI1-bound GGAA repeat en-
hancers (Supplemental Table S2), from which we selected
six candidate enhancers neighboring the genes that en-
code the transcription factors NKX2-2, SOX2, POU3F1,
and EGR2; the membrane protein NPY1R; and the inhib-
itor of phosphatase PPP1R1A. These enhancers were lo-
cated at variable genomic distances from their putative
target genes, ranging from 15 to 470 kb.
We first assessed chromatin changes mediated by
CRISPR dCas9-KRAB targeting unique sites adjacent to
GGAA repeats associated with the NKX2-2 and SOX2
genomic loci. Control cells exhibited strong signals for
EWS-FLI1 and the active chromatin mark H3K27ac at
these sites, whereas the repressive H3K9me3 mark was
not detected (Fig. 2A,B). Upon lentiviral transduction of
the tumor cells with CRISPR dCas9-KRAB constructs,
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Figure 1. EWS-FLI1-bound GGAA microsatellite repeats are transcriptionally active. (A) Box plots show NRO-seq read counts at inter-
genic GGAA microsatellite repeats in A673 Ewing sarcoma cells based on the number of consecutive repeats. Reads were counted in a
1-kb window centered on GGAA microsatellite repeats. (B) Composite plots show NRO-seq signals at intergenic GGAA repeats that
are either EWS-FLI1-bound (n = 473; left) or unbound (n = 7232; right) in A673 Ewing sarcoma cells. TheX-axis represents a 10-kb window
centered on GGAAmicrosatellite repeats. (C ) Heat maps show NRO-seq signal density in Ewing sarcoma A673 cells (left) and GRO-seq
signal density in BJ fibroblasts (right) at the top 300 transcriptionally active intergenic EWS-FLI1-boundGGAA repeats in A673 cells. Ten-
kilobasewindows in each panel are centered on EWS-FLI1-boundGGAA repeats. (D) RT–PCR shows the detection of eRNAs at EWS-FLI1-
bound GGAA repeats in Ewing sarcoma cells A673 and SKNMC. MRC5 fibroblasts were used as negative control cells. Additional neg-
ative controls lack reverse transcriptase or map to a nontranscribed region on chromosome 1. GAPDH was used as a positive control of
reverse transcription. Amplicon sizes are indicated in parentheses. (E) RT-qPCR shows the increased detection of eRNAs at EWS-FLI1-
bound GGAA repeats in SKNMC cells expressing Cas9 and single-guide RNAs (sgRNAs) targeting the EXOSC3 coding sequence. (Inset)
EXOSC3 and EWS-FLI1 protein levels assessed by immunoblotting in the same experiments. GAPDH was used as loading control. Cells
were collected 7 d after lentiviral transduction. (F ) Composite plots showNRO-seq signals at intergenic EWS-FLI1-bound GGAA repeats
(n = 473) in A673 cells 96 h after infection with either a control shRNA (plain line) or a shRNA targeting FLI1 (dotted line). Enhancers
found in intragenic regions or <5 kb from genes expressed in Ewing sarcoma were removed from consideration. The X-axis represents a
10-kb window centered on EWS-FLI1-bound GGAA microsatellite repeats. (G) Example shows decreased nascent transcription at an
EWS-FLI1-bound GGAA repeat enhancer near PPP1R1A in A673 cells infected with either a control shRNA (left) or a shRNA targeting
FLI1 (right). ChIP-seq (chromatin immunoprecipitation [ChIP] combined with high-throughput sequencing) tracks of FLI1 (EWS-FLI1),
H3K27ac, and NRO-seq. Regions of interest are highlighted in light gray. (∗) P-value < 0.05; (∗∗) P-value < 0.01. See also Supplemental
Figures S1 and S2.
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we observed substantial changes in chromatin marks at
the targeted sites. Consistent with histone deacetylase
and H3K9 methylase activities of the KRAB domain,
we observed the virtually complete disappearance of
H3K27ac signals, which were replaced by the focal
spread of H3K9me3 marks over a region of ∼3 kb adja-
cent to the targeted GGAA repeat (Fig. 2A,B). Remark-
ably, we also observed the disappearance of EWS-FLI1
signals (Fig. 2A,B), suggesting that the changes in chro-
matin state induced by our editing strategy were pro-
found enough to compete with the direct binding of the
oncogenic fusion protein. These results were further con-
firmed by ChIP-qPCR (chromatin immunoprecipitation
[ChIP] combined with qPCR) at the EWS-FLI1-bound
GGAA repeat associated with the SOX2 locus (Supple-
mental Fig. S4A).
ChIP-seq analysis of chromatin marks across all EWS-
FLI1-bound GGAA repeat enhancers revealed a high de-
gree of specificity for the observed changes in chromatin
marks at targeted loci. Notably, whereas we identified
pronounced increases in H3K9me3 and decreases in
H3K27ac marks at the corresponding targeted sites, other
EWS-FLI1-bound GGAA repeats remained virtually unaf-
fected in each experiment (Fig. 2C,D).
To further assess the functional impact of targeted epi-
genome editing on enhancer activity, wemeasured chang-
es in eRNA levels upon site-specific repeat silencing. As
expected, induction of chromatin-repressive states at
GGAA repeats resulted in transcriptional abrogation of
the corresponding eRNAs (Fig. 2E,F), whereas eRNA ex-
pression levels remained unaltered at other EWS-FLI1-
bound GGAA sites (Fig. 2E,F). In summary, our
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Figure 2. Site-specific GGAA repeat enhancer silencing using dCas9-KRAB. (A,B) ChIP-seq tracks of FLI1 (EWS-FLI1), H3K27ac, and
H3K9me3 signals over the NKX2-2 (A) and SOX2 (B) loci in A673 cells expressing dCas9-KRAB and a sgRNA targeting either the GFP
control sequence or GGAA repeat enhancers activated by EWS-FLI1 in Ewing sarcoma. Target regions are shown in light gray, and loca-
tions of sgRNA-binding sites are illustrated by a black box. (C,D) Scatter plots show the H3K9me3 and H3K27ac changes observed by
ChIP-seq at EWS-FLI1-boundGGAA repeat enhancers (n = 812) inA673 cells lentivirally inducedwith dCas9-KRAB and sgRNAs targeting
enhancers nearNKX2-2 (C ) or SOX2 (D). A red dot for H3K9me3 and a green dot for H3K27ac show the positions of the targeted enhancers
in each experiment. Signals were calculated over a 5-kb window centered on EWS-FLI1-bound GGAA repeats. (E,F ) RT-qPCR shows the
specific decreases of eRNA levels at targeted EWS-FLI1-boundGGAA repeat enhancers nearNKX2-2 (E) or SOX2 (F ) in Ewing sarcoma cell
lines (A673 and SKNMC). Cells were collected 7 or 8 d after lentiviral transduction. (∗) P-value < 0.05; (∗∗) P-value < 0.01. See also Supple-
mental Figures S3 and S4A.
Epigenome editing of microsatellite enhancers
GENES & DEVELOPMENT 1011
 Cold Spring Harbor Laboratory Press on August 7, 2018 - Published by genesdev.cshlp.orgDownloaded from 
observations suggest that site-specific epigenetic silenc-
ing of genomic repeats by CRISPR dCAS9-KRAB provides
a powerful and selective approach to evaluate the func-
tional role of repetitive genomic elements in cancer.
Site-specific silencing of GGAA repeat enhancers
strongly decreases the expression of putative target
genes in Ewing sarcoma
Having demonstrated robust changes in activity at specif-
ically targeted GGAA repeats through epigenome silenc-
ing, we next sought to determine the impact on their
putative target gene expression. We found that NKX2-2
and SOX2 transcripts and proteins levelswere strongly de-
creased upon targeting of their corresponding repeat ele-
ments (Fig. 3A,B, left and right, respectively), whereas
expression of other GGAA repeat-associated genes re-
mained stable (Supplemental Fig. S4B).
These observations were further expanded by targeting
four additional GGAA repeat enhancers located near the
PPP1R1A, NPY1R, POU3F1, and EGR2 gene loci. Each
of these EWS-FLI1-bound repeat sites was silenced using
two specific single-guide RNAs (sgRNAs) in two Ewing
sarcoma cell lines (Fig. 3C–F, top panel). Similar to the re-
sults obtained with NKX2-2 and SOX2, silencing of addi-
tional GGAA repeat enhancers invariably resulted in a
marked decrease in expression of their associated genes
(Fig. 3C–F, bottom panel) without altering the transcrip-
tional profile of other repeat-associated genes (Sup-
plemental Fig. S4B). These experiments strongly support
the strength and specificity of our enhancer targeting
strategy and identify the major functional role played by
GGAA repeat enhancers in regulating the expression of
their putative target genes.
Silencing Ewing sarcoma-specific microsatellite
enhancers does not affect gene expression
in unrelated cells
Enhancer elements represent cell type-specific distal reg-
ulatory units capable of coordinating the precise spatio–
temporal distribution of gene expression required to
define different cell states. EWS-FLI1-boundGGAA repeat
enhancers were found to be specifically active only in
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Figure 3. EWS-FLI1-boundGGAA repeat enhancers directly control putative target gene expression. (A,B)NKX2-2 and SOX2mRNAand
protein levels assessed by RT-qPCR (left) and immunoblotting (right), respectively, in two Ewing sarcoma cell lines (SKNMC and A673)
expressing dCas9-KRAB and a sgRNA targeting GGAA repeat enhancers activated by EWS-FLI1 near NKX2-2 or SOX2. sgRNAs against
GFPwere used as controls. Protein levels are quantified by immunoblots. (C–F, top) ChIP-seq tracks of FLI1 (EWS-FLI1) andH3K27ac over
putative target genes and associated GGAA repeat enhancers activated by EWS-FLI1 in Ewing sarcoma. Target regions are shown in light
gray, and locations of sgRNA-binding sites are illustrated by a black box. (Bottom) Expression levels of putative target genes assessed by
RT-qPCR in two Ewing sarcoma cell lines (SKNMC and A673) expressing dCas9-KRAB and a sgRNA targeting either GFP or neighboring
GGAA repeat enhancers activated by EWS-FLI1 in Ewing sarcoma. Cells were collected 7 or 8 d after lentiviral transduction. (∗) P-value <
0.05; (∗∗) P-value < 0.01. See also Supplemental Figure S4B.
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Ewing sarcoma among a large collection of normal and
tumor cell types (Riggi et al. 2014). Consistent with this
observation, the transcriptional effects observed upon
site-specific GGAA repeat silencing (Fig. 3) should be re-
stricted to Ewing sarcoma cells and not detected in other
cell types. To confirm this hypothesis, the dCas9-KRAB
construct and specific sgRNAs for NKX2-2 and SOX2 re-
peat enhancers were transduced into a lung cancer cell
line,NCI-H810, known to express high levels of both tran-
scripts (Fig. 4A,B). As expected, since these cells do not ex-
press EWS-FLI1 (Fig. 4B), ChIP-seq analysis of their
H3K27ac distribution failed to show any hallmarks of ac-
tive enhancers at GGAA repeat sites near these gene loci
(Fig. 4C; Supplemental Fig. S5A). Accordingly, despite the
efficient deposition of the H3K9me3 marks at the same
sites, as detected by ChIP-qPCR (Fig. 4D; Supplemental
Fig. S5B), no effect was observed on either SOX2 or
NKX2-2 mRNA and protein levels in NCI-H810 cells
(Fig. 4E; Supplemental Fig. S5C), confirming the high
selectivity of this targeting strategy that relies on the
cell type-specific enhancer landscape.
Silencing a Ewing sarcoma-specific microsatellite
enhancer decreases de novo induction of NKX2-2 in
MSCs
Wenext consideredwhether repression of a GGAAmicro-
satellite repeat in non-Ewing sarcoma cells could prevent
gene activation by EWS-FLI1. For these experiments, we
turned to MSCs, in which NKX2-2 expression is virtually
undetectable but becomes strongly induced upon lentivi-
ral transduction of EWS-FLI1 and the concomitant activa-
tion of the associated GGAA repeat enhancer (Fig. 5A).
MSCs were initially transduced with dCas9-KRAB and a
specific sgRNA targeting the GGAAmicrosatellite repeat
near the NKX2-2 locus and subsequently lentivirally in-
fected with EWS-FLI1 (Fig. 5B,C). Consistent with our re-
sults in Ewing sarcoma cells (Fig. 3), NKX2-2 induction
was strongly impaired, whereas expression of other
EWS-FLI1 target genes remained unaltered (Fig. 5D).
Altogether, our results demonstrate that GGAA repeat
sites can be converted by EWS-FLI1 into fully active en-
hancer elements (which strongly influence the regulation
C
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Figure 4. Silencing a Ewing sarcoma-specific GGAA repeat enhancer does not affect SOX2 expression levels in NCI-H810 lung cancer
cells. (A,B)NKX2-2 and SOX2 are expressed at similar levels in lung carcinomaNCI-H810 cells and Ewing sarcomacells. RT-qPCR (A) and
immunoblotting (B) show similar expression levels. EWS-FLI1 is detected only in A673 and SKNMC Ewing sarcoma cells. GAPDH was
used as loading control. (C ) ChIP-seq for H3K4me3 and H3K27ac (A673 and NCI-H810) and FLI1 (EWS-FLI1) (A673) shows that an EWS-
FLI1-bound GGAA repeat near SOX2 is specifically active in Ewing sarcoma. (D) ChIP-qPCR experiments confirm the absence of
H3K27ac and the deposition of H3K9me3 at a Ewing sarcoma-specific enhancer near SOX2 in lentivirally transduced NCI-H810 cells
with dCas9-KRAB and a sgRNA targeting either the GFP control sequence or the GGAA repeat site near SOX2. (E) RT-qPCR and immu-
noblotting show that targeting of a Ewing sarcoma-specific repeat enhancer near SOX2 inNCI-H810 cells does not affect SOX2 expression
levels in the same experiments. LAMIN A/C was used as loading control. Cells were collected 8 or 10 d after lentiviral transduction.
(∗) P-value < 0.05. See also Supplemental Figure S5.
Epigenome editing of microsatellite enhancers
GENES & DEVELOPMENT 1013
 Cold Spring Harbor Laboratory Press on August 7, 2018 - Published by genesdev.cshlp.orgDownloaded from 
of target gene expression) and that the transcriptional ef-
fects resulting from site-specific epigenome editing can
be tumor-specific.
Silencing of a single specific GGAA repeat enhancer can
inhibit tumor growth in vivo
Finally, to measure the biological contribution of a single
GGAA microsatellite repeat enhancer in Ewing sarcoma,
we asked whether epigenome silencing of an intergenic
GGAA site might be sufficient to impair tumor growth
in vivo. Among the panel of six repeat enhancers shown
to control EWS-FLI1-induced genes in our experiments
(Fig. 3), we selected the repeat enhancer that regulates
SOX2 expression from a distance of 470 kb, based on our
previous demonstration that this target gene plays an on-
cogenic role in Ewing sarcoma (Riggi et al. 2010; Ren et al.
2016).
In order to test the role of this GGAA repeat enhancer
on xenograft tumor growth, A673 and SKNMCEwing sar-
coma cells were transduced with dCas9-KRAB along with
two sgRNAs targeting the enhancer, selected with puro-
mycin, and injected subcutaneously into the flanks
of NOD-scidγ (NSG) mice (Fig. 6A). Remarkably, we ob-
served a marked decrease in both the weight and volume
of the xenografts derived from tumor cells subjected to en-
hancer silencing for bothA673 and SKNMCcell lines (Fig.
6B,C).
Taken together, our results demonstrate that individual
GGAA microsatellite enhancers activated by EWS-FLI1
constitute key requirements for the establishment of the
Ewing sarcoma oncogenic regulatory program and can
be selectively disrupted using site-specific epigenome-ed-
iting technologies.
Discussion
Active GGAA repeat elements are a major feature of the
chromatin landscape induced by EWS-FLI1 in Ewing sar-
coma, but their function as distal regulatory elements
has not been tested. Our studies demonstrate that epi-
genome editing can be used to silence repeat elements
and directly demonstrate that specific GGAA repeats per-
form critical gene regulation functions in Ewing sarcoma
by operating as powerful distal enhancers. Importantly,
since the activation of GGAA microsatellite repeats is a
neomorphic property of EWS-FLI1 that is not shared by
the wild-type transcription factor FLI1 (Boulay et al.
2017), the regulatory activity of these repeat elements
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Figure 5. Silencing a Ewing sarcoma-specific GGAA repeat enhancer impairs de novo induction of NKX2-2 in MSCs. (A) ChIP-seq for
FLI1 (EWS-FLI1) in A673 cells and FLI1 (EWS-FLI1), H3K27ac, H3K4me3, and H3K4me1 in MSCs lentivirally transduced with a control
vector or EWS-FLI1. EWS-FLI1 can activate a GGAA repeat enhancer nearNKX2-2. (B) Schematic showing the experimental strategy used
in our assays. MSCs were lentivirally transduced with dCas9-KRAB and either sgRNA control (GFP) or a sgRNA targeting the EWS-FLI1-
bound GGAA repeat enhancer nearNKX2-2 before EWS-FLI1 lentiviral induction. (C ) Immunoblotting confirms EWS-FLI1 expression in
MSCs upon lentiviral induction.GAPDHwas used as loading control. (D) RT-qPCR shows the specific decreasedmRNA levels ofNKX2-2
in MSCs infected with dCas9-KRAB and a sgRNA targeting the Ewing sarcoma-specific GGAA repeat enhancer site nearNKX2-2 before
EWS-FLI1 induction. SOX2, EZH2, andNR0B1 are other EWS-FLI1-induced genes not affected in these experiments.XRN2was used as a
control gene. (∗∗) P-value < 0.01.
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represents a tumor-specific mechanism that may be ex-
ploited for the development of new therapies. Considering
the increasing evidence of repeat element dysregulation in
cancer, our results also raise the possibility that repeats
may be associated with enhancer functions in other tu-
mor types. As in the case of Ewing sarcoma, the activity
of specific repeats may be intimately connected with on-
cogenic events and thus may also point to therapeutic
opportunities.
Unlike many instances where distal regulatory ele-
ments are part of complex networks and make only incre-
mental contributions to the expression of their associated
target genes, our studies directly demonstrate that indi-
vidual GGAA microsatellite repeat sites activated by
EWS-FLI1 can be major determinants of gene expression.
Indeed, the enhancers selected for testing were located
near some of the genes that are most highly responsive
to the presence of EWS-FLI1, and our epigenome-editing
experiments showed major effects on gene activation.
Moreover, the lack of expression of these genes in MSCs
and their association with repressive chromatin marks
in these cells suggest that their expression is induced de
novo by GGAA repeat enhancers during transformation
by EWS-FLI1.
The importance of the powerful regulatory effectsmedi-
ated by individual GGAA repeat elements is further
supported by our finding that silencing a single microsat-
ellite located 470 kb distal to SOX2 is sufficient to impair
tumor growth. Our data further show that silencing this
same site in unrelated cells did not affect gene expression
and thus are in keeping with the fact that GGAA repeats
do not appear to have open chromatin in a diverse panel
of cell lines (Riggi et al. 2014). Individual repeat enhancers
thus may constitute vulnerabilities that are specific to
cancer cells, and strategies aimed at targeting these sites
individually or in combination could have therapeutic
value and a large therapeutic window. Importantly, in
the context of efforts aimed at targeting EWS-FLI1 itself,
EWS-FLI1-bound GGAA repeats observed genome-wide
represent a large set of additional tumor-specific targets
that may be effective even in cases of resistance to EWS-
FLI1-directed therapies.
Our results show that the combination of epigenome
profiling and functional testing with dCas9-KRAB pro-
vides an effective strategy for identifying functional repeat
elements. Epigenome profiling has shown previously that
a large fraction of EWS-FLI1-binding events occurs at
GGAA microsatellites, where the fusion protein induces
chromatin marks typical of active enhancers (Gangwal
et al. 2008; Riggi et al. 2014; Tomazou et al. 2015). Our
NRO-seq profiles now show that a subset of EWS-FLI1-
bound GGAA microsatellites is transcribed and produces
eRNAs, which recently have been closely linked to func-
tional enhancer activity and chromatin looping (Li et al.
2016). As demonstrated in our experiments, candidate re-
peat loci identified through these methodologies can be
effectively tested by targeting unique sequences adjacent
tomicrosatellites with dCas9-KRAB. Our ChIP-seq profil-
ing and recent studies in other systems (Thakore et al.
2015) show limited local spreading of H3K9me3 marks
upon introduction of dCas9-KRAB. This is sufficient for
repeat silencing, and the reduction in spatial resolution
compared with CRISPR–Cas9 targeting is compensated
for by the ability to specifically inactivate a single geno-
mic location containing a repeat sequence. In addition, si-
lencing is achieved without inducing DNA damage,
thereby avoiding the risk of nonspecific effects on cell vi-
ability (Aguirre et al. 2016; Munoz et al. 2016).
A
C
B Figure 6. Silencing of a GGAA repeat en-
hancer reduces Ewing sarcoma tumor
growth in vivo. (A) Schematic showing the
experimental strategy used in our assays.
Ewing sarcoma cells (A673 and SKNMC)
were lentivirally transduced with dCas9-
KRAB and either sgRNA control (GFP) or a
sgRNA targeting a EWS-FLI1-bound
GGAA repeat enhancer neighboring SOX2
before subcutaneous injection in immuno-
compromised NSG mice. (B,C ) Inhibition
of a repeat microsatellite enhancer near
SOX2 markedly reduces tumor growth in
immunocompromised mice, as assessed by
tumor weight (B) and volume (C ) 3 wk after
subcutaneous injection. Six tumors were as-
sayed per condition. (∗) P-value < 0.05; (∗∗) P-
value < 0.01.
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Interestingly, effective targeting using dCas9-KRAB
also provides an opportunity to gain mechanistic insights
beyond functional validation of specific enhancers. For ex-
ample, the fact that dCas9-KRAB was sufficient to evict
EWS-FLI1 from GGAA repeat microsatellites suggests
that the removal of histone acetylation and the accumula-
tion of H3K9me3 can induce a chromatin environment
that prevents EWS-FLI1 binding toDNA. This was further
supported by experiments in which dCAS9-KRAB target-
ing preceding the introduction of EWS-FLI1 strongly de-
creased the induction of NKX2-2 by the fusion protein
in MSCs. The absence of H3K9me3 at GGAAmicrosatel-
lite repeats thus may be a prerequisite for EWS-FLI1 pio-
neer activity leading to enhancer activation during the
first steps of transformation and may be an important fea-
ture of the cells of origin of Ewing sarcoma.
In conclusion, our studies establish a methodology
for silencing repeat elements and directly demonstrate
that GGAA microsatellites activated by EWS-FLI1 oper-
ate as powerful distal regulatory elements in Ewing sar-
coma. These findings also suggest that the dysregulation
of repeat elements in other tumor types may have impor-
tant consequences for oncogenic gene expression pro-
grams. The systematic functional characterization of
tumor-specific regulatory elements through epigenome
editing thus may point to vulnerabilities that could be ex-
ploited for the development of new therapies in many
types of cancer.
Materials and methods
MSCs and tumor spheres
MSCs and primary tumor samples were collected with approval
from the Institutional Review Board of the Centre Hospitalier
Universitaire Vaudois (University of Lausanne). Samples were
deidentified prior to our analysis. Primary bone marrow-derived
MSCs were cultured in Iscove’s modified Dulbecco’s medium
(IMDM) containing 10% fetal calf serum (FCS) and 10 ng/mL
platelet-derived growth factor BB (PeproTech). Ewing sarcoma pa-
tient-derived tumor spheres were cultured in IMDM (Gibco) sup-
plemented with 20% knockout serum (Gibco), 10 ng/mL human
recombinant EGF and bFGF (Invitrogen), and 1%penicillin/strep-
tomycin (Gibco) in ultralow attachment flasks (Corning), as
described previously (Suva et al. 2009).
Cell lines
Cell lines were obtained fromAmerican Type Culture Collection
(ATCC), andmedia were obtained from Life Technologies. Ewing
sarcoma cell lines SKNMC and A673 were grown in RPMI. NCI-
H810 and MRC5 cells were grown in RPMI and EMEM, respec-
tively. All media were supplemented with 10% FBS, and cells
were cultured at 37°C with 5% CO2. Cells were maintained
and split every 2–3 d according to ATCC’s recommendations.
Definition of genes induced by EWS-FLI1
Genes strongly induced by EWS-FLI1were defined fromprevious-
ly generated RNA-seq data (Boulay et al. 2017) based on the fol-
lowing criteria: (1) greater than threefold decrease upon EWS-
FLI1 knockdown in both A673 and SKNMCEwing sarcoma cells,
(2) greater than threefold increase in MSCs lentivirally induced
with EWS-FLI1 (DESeq2-corrected P-value of <0.05) (Love et al.
2014), and (3) expression values of at least 1 FPKM (fragments
per kilobase permillionmapped fragments) in A673 and SKNMC
cells prior to EWS-FLI1 knockdown and in MSCs upon lentiviral
induction with EWS-FLI1. Differences in expression between
Ewing sarcoma tumor samples and normal tissues were calculat-
ed for 92 induced genes present in publicly available microarray
data (GSE: GSE68776) (Svoboda et al. 2014) and are displayed in
a row-normalized heat map (Supplemental Fig. S3B). Distances
between transcription start sites (TSSs) and EWS-FLI1-bound
GGAA repeats (Supplemental Fig. S3C; Riggi et al. 2014) were
compared with nonresponsive genes (minimum expression of
1 FPKM in A673 and SKNMC Ewing cell lines and log2 fold
change expression of <0.3 in knockdown and up-regulation
experiments).
Annotation of GGAA microsatellite repeats
GGAA repeats were defined as intervals with four or more con-
secutive GGAA/TTCC units in the human genome (hg19) using
BedTools (Quinlan and Hall 2010). Repeat intervals within 100
bases of each other were merged prior to further processing. In
Figure 1, A and B, and Supplemental Figure S1, A and B, we fo-
cused our analysis on distal sites by excluding microsatellite re-
peats within 5000 bases from the boundaries of RefSeq-
annotated genes and sites with high H3K4me3 ChIP-seq signals
(more than eight normalized units in either A673 or SKNMC)
to account for unannotated gene promoters. Each category con-
tained 4126, 637, 700, 632, 608, 412, 227, and 363 sites, respec-
tively. EWS-FLI1-bound GGAA repeats were defined based on
EWS-FLI1 ChIP-seq as before (Riggi et al. 2014). In Figure 1C
and Supplemental Figure S1D, the same exclusion criteria were
applied to EWS-FLI1-bound GGAA repeats. In Supplemental
Figure S1C, for comparison of NRO signals at EWS-FLI1-bound
GGAA repeats versus other active enhancers, we applied the
same exclusion criteria as above toH3K27ac peaks in order to iso-
late distal peaks and identified two categories: (1) peaks intersect-
ing EWS-FLI1-bound GGAA repeats (Riggi et al. 2014) and (2)
peaks that are not bound by EWS-FLI1 and do not contain four
or more GGAA repeat units.
Definition of targetable EWS-FLI1-bound GGAA repeat enhancers
The set of targetable EWS-FLI1-bound GGAA repeat enhancers
(Supplemental Table S2) was obtained by identifying EWS-FLI1-
bound GGAA repeat enhancers (Riggi et al. 2014) within 500 kb
of the 111 EWS-FLI1-induced genes defined above. Genes whose
nearest enhancer lies within 5 kb of any gene expressed
(>1 FPKM) in either A673 or SKNMC cells were removed from
this analysis. When several candidate enhancers were assigned
to a gene, we chose to target the most active site based on
H3K27ac ChIP-seq levels.
V2-dCas9-KRAB and guide RNA cloning
The V2-dCas9-KRAB construct was generated by replacing wild-
type Cas9 from V2-Cas9 plasmid (Addgene, 52961) with mutant
dCas9-KRAB (Addgene, 60954). Cas9 was removed from the V2-
Cas9 plasmid using BamH1 and Xba1. dCas9-KRAB was ex-
tracted using Nhe1 and partial BamH1 digestion. The plasmid
sequence was verified using next-generation sequencing (Mas-
sachusetts General Hospital Center for Computational and Inte-
grative Biology [CCIB] DNA Core). sgRNAs were cloned into
V2-dCas9-KRAB following standard protocols.
Boulay et al.
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Lentiviral generation
Lentivirus was produced in 293T LentiX cells (Clontech) by LT1
(Mirus Bio) transfection with gene delivery vector and packaging
vectorsGAG/POLandVSVplasmids.Viral supernatantswerecol-
lected 72 h after transfection and concentrated using LentiX con-
centrator (Clontech). Virus-containing pellets were resuspended
inPBS andaddeddropwise oncells in thepresence ofmediumsup-
plemented with 6 µg/mL polybrene. Selection of lentivirally in-
fected cells was achieved with puromycin used at 0.75 µg/mL
for MSCs, 1 µg/mL for SK-N-MC, 2 µg/mL for A673, and 4 µg/
mL for NCI-H810. Overexpression or knockdown efficiency was
determined by Western blot analysis and RT-qPCR.
RT-qPCR
For gene expression assays, total RNAwas isolated from cells us-
ing NucleoSpin RNA Plus (Clontech). cDNAwas obtained using
SuperScript VILO cDNA synthesis kit (Thermo Fisher Scientific).
One microgram of template total RNA and random hexamers
were used for each reaction. Real-time PCR amplification was
performed using fast SYBRGreenmaster mix (Life Technologies)
and specific PCR primers in a LightCycler 480 instrument
(Roche). The oligonucleotides used are shown in Supplemental
Table S3. Relative quantification of each target, normalized to
an endogenous control (GAPDHorHPRT1), was performed using
the comparative Ctmethod (Applied Biosystems). Error bars indi-
cate the standard deviation of three technical replicates and
represent at least two independent biological experiments. Statis-
tical analyses were performed by Student’s t-test. In heat maps
(Supplemental Fig. S4B), log2 RT-qPCR expression values were
averaged across biological replicates in each condition.
Western blot analysis
Western blotting was performed using standard protocols. Prima-
ry antibodies used forWestern blotting are listed in Supplemental
Table S3. Secondary antibodies were goat anti-rabbit, anti-mouse
(Bio-Rad), and anti-rat (Invitrogen) immunoglobulin G-horserad-
ish peroxidase-conjugated (1:10,000 dilution). Membranes were
developed usingWestern Lightning Plus-ECL enhanced chemilu-
minescence substrate (PerkinElmer) and visualized using photo-
graphic film.
ChIP-seq
ChIP assays were carried out on A673, MSCs, and NCI-H810 cul-
tures of ∼2 million to 5 million cells per sample and per epitope,
following the procedures described previously (Mikkelsen et al.
2007). In brief, chromatin from formaldehyde-fixed cells was frag-
mented to a size range of 200–700 bases with a Branson 250 soni-
fier. Solubilized chromatin was immunoprecipitated with the
indicated antibodies overnight at 4°C. Antibody–chromatin com-
plexes were pulled down with protein G Dynabeads (Life Tech-
nologies), washed, and then eluted. After cross-link reversal and
RNase A and proteinase K treatment, immunoprecipitated
DNA was extracted with AMP Pure beads (Beckman Coulter).
ChIP DNA was quantified with Qubit. ChIP DNA samples (1–5
ng) were used to prepare sequencing libraries, and ChIP DNA
and input controls were sequenced with the NextSeq 500 Illu-
mina genome analyzer.
ChIP-seq bioinformatic processing
Reads were aligned to hg19 using bwa (Li and Durbin 2009).
Aligned reads were then filtered to exclude PCR duplicates and
extended to 200 base pairs (bp) to approximate fragment sizes.
Density maps were generated by counting the number of frag-
ments overlapping each position using igvtools, and normalized
to 10 million reads. Average ChIP-seq signals across intervals
were calculated using bwtool (Pohl and Beato 2014). Signals
shown in heat maps (100-bp windows) and composite plots
(10-bp window) were calculated using bwtool (Pohl and Beato
2014). Heat map signals are in log2 scale, centered on the TSS of
EWS-FLI1-induced genes, and capped at the 99th percentile.
ChIP-qPCR
ChIP was performed as described above. qPCRwas performed us-
ing fast SYBR Green master mix (Life Technologies) and specific
PCR primers in a LightCycler 480 instrument (Roche). The oligo-
nucleotides used are shown in Supplemental Table S3. Relative
quantification of each target, normalized to input control, was
performed using the comparative Ct method (Applied Biosys-
tems). Error bars indicate the standard deviation of three techni-
cal replicates and represent at least two independent biological
experiments.
NRO assay
NRO assays were performed as described recently (Roberts et al.
2015) with minor modifications. Briefly, cells were collected by
cold trypsinization and washed with cold PBS before counting,
and 10 million to 15 million cells were aliquoted per reaction.
Nuclei were isolated in NP-40 lysis buffer (10 mM Tris-HCl at
pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40) for 5 min on
ice, sedimented by centrifugation at 300g for 4 min at 4°C, and
resuspended in 100 µL of nucleus storage buffer (50 mM Tris-
HCl at pH 8, 0.1 mM EDTA, 5 mM MgCl2, 40% glycerol).
NRO transcriptionwas performed for 30min at 30°C after adding
150 µL of transcription buffer (20 mM Tris-HCl at pH 8, 5 mM
MgCl2, 300 mM KCl) supplemented with 4 mM fresh DTT
(Sigma-Aldrich), 3.33 mM ATP, 1.66 mM UTP, 3.33 mM CTP,
3.33 mM GTP, 1.66 mM BrUTP (Roche), and 100 U of RNase-
OUT (Life Technologies). Nuclear RNA was isolated using
NucleoSpin microRNA kit (Clontech). For each immunoprecipi-
tation, 30 µL of protein G Dynabeads (Life Technologies) was
washed twice in PBST (1× PBS, 0.1% Tween-20) and incubated
with rotation for 10 min at room temperature with 2 µg of
anti-BrdU monoclonal antibody (Santa Cruz Biotechnology).
Next, 150 µL of blocking buffer (PBST supplemented with
0.1% polyvinylpyrrolidone [Sigma-Aldrich] and 0.1% UltraPure
BSA [Life Technologies]) was added, and the reaction was incu-
bated with rotation for 30 min longer at room temperature.
Anti-BrdU-bound beads were collected using a magnet and resus-
pended in 100 µL of PBSTR (PBST supplemented with 8 U/mL
RNaseOUT). Six micrograms of NRO-RNA was denatured for 5
min at 65°C, mixed with anti-BrdU-bound beads, and incubated
with rotation for 30 min at room temperature. Immunocom-
plexes were collected using a magnet and washed three times
with PBSTR. Finally, purified RNAwas isolated using the Nucle-
oZOL extraction kit (Clontech) and eluted in 20 µL of ultrapure
water.
NRO-RT-qPCR
Ten microliters of purified NRO-RNA or 600 ng of nuclear input
RNA was used for each reaction. cDNA was obtained using Su-
perScript VILO cDNA synthesis kit with random hexamers
(Thermo Fisher Scientific). Real-time PCR amplification was per-
formed using fast SYBR Green master mix (Life Technologies)
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and specific PCR primers in a LightCycler 480 instrument
(Roche). The oligonucleotides used are shown in Supplemental
Table S3. Relative quantification of each target, normalized to
an endogenous control (GAPDHorHPRT1), was performed using
the comparative Ctmethod (Applied Biosystems). Error bars indi-
cate the standard deviation of three technical replicates. Statisti-
cal analyses were performed by Student’s t-test.
NRO-seq
For NRO-seq, NROwas performed as described above, but five to
10 immunoprecipitations were simultaneously prepared and
pooled before final RNA purification. Ninemicroliters of purified
NRO-RNA was treated with RiboGone oligonucleotides to re-
move ribosomal RNA (Clontech). Illumina-compatible sequenc-
ing libraries were constructed using SMARTer stranded total
RNA sample preparation kit (Clontech) according to the manu-
facturer’s instructions and sequenced with the NextSeq 500 Illu-
mina genome analyzer.
NRO-seq and GRO-seq bioinformatic processing
Reads were aligned to GRCh37(hg19) using bwa-mem (Li
2013). PCR duplicates were removed using Picard (http://
broadinstitute.github.io/picard). We generated read count totals
in each interval (Fig. 1A; Supplemental Fig. S1A,C) as well as ge-
nome-wide signals (Fig. 1B,C,F,G; Supplemental Fig. S1B,D,G) us-
ing BedTools coverage. Strand-specific signals were generated
from bam files obtained by separating reads that aligned to for-
ward and reverse strands. Genome-wide smoothed signals were
generated by counting reads in 150-bp sliding windows with
20-bp overlap. All signals were normalized for sequencing depth
and scaled to 10 million reads. GRO-seq data for BJ cells were ob-
tained from Gene Expression Omnibus (GEO; GSE96717) (Slobo-
din et al. 2017) and processed identically to NRO-seq data. In
Supplemental Figure S1E, GRO-seq peaks were called in BJ cells
with MACS2 using a ChIP-seq input as a background control
(GEO: ENCSR000DQE/ENCFF001HAG). Intergenic sites were
defined by excluding intervals that fell within 5000 bases from
the boundaries of RefSeq-annotated genes (TSS− 5000 to tran-
scription end site + 5000). In order to account for unannotated
gene promoters, we also excluded intervals that had an average
normalized H3K4me3 ChIP-seq signal >8 in BJ cells (GEO:
ENCSR000DWS/ ENCFF001FZQ).
In vivo tumorigenic assays
For in vivo experiments, A673 and SKNMC cells were infected
with lentiviral vectors expressing dCas9-KRAB and sgRNAs tar-
geting either the GFP sequence (control) or the GGAA repeat en-
hancer identified near the SOX2 locus. After 48 h of puromycin
selection, 1 × 106 cells for each condition were injected subcuta-
neously into NOD-scid IL2Rγnull mice (The Jackson Laboratory).
Mice weremonitored daily for tumor development and sacrificed
3 wk later, when tumor weight and volumewere assessed. Exper-
imental protocols involving mice were approved by the Veteri-
nary Service of the Canton of Vaud, Switzerland (Etat de Vaud,
Service Vétérinaire), under authorization number VD2488. Stat-
istical analyses were performed by Student’s t-test.
Quantification and statistical analysis
All statistical details of experiments are included in the figure leg-
ends or specific Materials and Methods section.
Data and software availability
The data accompanying this study have been deposited into GEO
under accession number GSE106925.
Additional resources
To aid our analysis, we also used our publicly available data sets
for EWS-FLI1, H3K4me1, H3K4me3, and H3K27ac ChIP-seq in
A673 and SKNMC cells (GEO:GSE61953) (Riggi et al. 2014) and
RNA-seq in A673, SKNMC, andMSCs (GEO: GSE94278) (Boulay
et al. 2017).We also used publicly available data sets for GRO-seq
in BJ cells (GEO: GSE96717) (Slobodin et al. 2017), H3K4me3
ChIP-seq in BJ cells (ENCODE: ENCSR000DWS/ENCFF001FZQ)
and its matched input control (ENCODE: ENCSR000DQE/
ENCFF001HAG), expression microarray in Ewing sarcoma
tumor samples and normal tissues (GEO: GSE68776) (Svoboda
et al. 2014), and Cancer Cell Line Encyclopedia (https://data.
broadinstitute.org/ccle_legacy_data/mRNA_expression/CCLE_
Expression_Entrez_2012-09-29.gct; Barretina et al. 2012).
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